Research news · menopause and cancer-prevention therapy
Estrogen and hot flashes: what a new analysis of the MAP.3 trial found
A study of estrogen and hot flashes, published online Nov 11, 2026 in ESMO Open, looked at baseline blood estrogen in 4,111 postmenopausal women from the MAP.3 breast-cancer prevention trial. It asked whether higher estrogen at the start was linked to more severe hot flashes in women taking exemestane. This page summarizes the published abstract. It is not advice about hormone therapy, and an antiperspirant does not treat hot flashes.
Estrogen and hot flashes at a glance
- Researchers measured baseline estrone (E1) and estradiol (E2) in stored serum from 4,111 postmenopausal women in the placebo-controlled MAP.3 exemestane trial (ESMO Open; PubMed abstract).
- Among women on exemestane, those in the highest estrogen quartile were more likely to have severe hot flashes in year 1 than those in the lowest quartile (E1 odds ratio 3.8; E2 odds ratio 4.2), with a dose-response at year 1. There were no significant associations in the placebo group.
The study question
Why researchers studied estrogen and hot flashes
Aromatase inhibitors such as exemestane can help prevent breast cancer in some postmenopausal women, but menopause-related side effects can make it hard to stay on treatment. The authors hypothesized that estrogen levels measured at baseline might help predict those side effects. Symptoms were graded with the Common Terminology Criteria for Adverse Events, version 4.0.
Other findings
Estrogen and hot flashes were not the only outcomes
Severe joint pain was also associated with higher baseline E1 and E2 in women on exemestane at year 1; the abstract says this was statistically significant only for E1 (quartiles 2 and 3). Women in the highest E1 or E2 quartile were more likely to stop study therapy within 12 months, independent of which treatment they were assigned. The authors say women with elevated estrogen who start exemestane may need extra support so they do not stop early.
FAQ
Estrogen and hot flashes: quick answers
What did this study find about estrogen and hot flashes?
Does this mean estrogen and hot flashes are a simple cause-and-effect pair?
Can an antiperspirant treat estrogen and hot flashes?
Should I change my cancer-prevention medicine because of estrogen and hot flashes?
How complete is this summary of estrogen and hot flashes research?
What the estrogen and hot flashes analysis measured
The paper is by Ho, Pasquet, Singh, Goetz, Tu, Ingle, Richardson and the MAP.3 Investigators, from the University of Montreal, Mayo Clinic and Queen’s University / Canadian Cancer Trials Group. Baseline E1 and E2 were measured by liquid chromatography with tandem mass spectrometry. Logistic regression estimated odds ratios for symptoms at years 1 and 5 (ESMO Open).
For severe hot flashes in year 1 among women on exemestane, the abstract reports an odds ratio of 3.8 for the highest vs lowest E1 quartile (95% confidence interval 1.6–10.5) and 4.2 for E2 (95% confidence interval 1.6–13.1).
Limits of this estrogen and hot flashes study
This is an observational analysis of a randomized trial, not a new treatment study. The associations were not seen on placebo for the symptom outcomes described. We did not review the full text, so limitations listed only in the paper are not summarized here. The findings should not be used to guide underarm-sweat products or to replace a clinician’s advice.
Estrogen and hot flashes are not the same as underarm sweating
Hot flashes and night sweats are not the same as ordinary underarm sweating. For more on menopause-related symptoms, see menopause hot flashes and night sweats guidance, menopause night sweats vs underarm sweating and medically induced menopause.
Sources
- Ho V, Pasquet R, Singh RJ, Goetz MP, Tu D, Ingle JN, Richardson H; MAP.3 Investigators. Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial. ESMO Open. 2026 Nov 11;11(11):108636. doi: 10.1016/j.esmoop.2026.108636 (online ahead of print)
- PubMed abstract, PMID 43014084 (the source we were able to read)
Educational information, not a diagnosis or medical advice. The abstract was read on Nov 12–13, 2026. This summary is based on the published abstract only; it is not evidence for any Maxim product.
Questions about estrogen and hot flashes?
Talk with the clinician who manages your menopause or cancer-prevention care. This page cannot decide treatment for you.
What the analysis measuredRead the sourcesEducational information only, not medical advice. The study did not test Maxim or any consumer product, and Maxim makes no claim to treat hot flashes, change estrogen levels or replace medical care.